CERo Therapeutics Holdings, Inc. (CERO)
NASDAQ: CERO · Real-Time Price · USD
0.9250
+0.0349 (3.92%)
At close: Apr 28, 2025, 4:00 PM
0.9308
+0.0058 (0.63%)
Pre-market: Apr 29, 2025, 7:31 AM EDT

CERO Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
10.733.952.840.43
Research & Development
5.473.72--
Other Operating Expenses
--0.060.14
Operating Expenses
16.27.682.910.57
Operating Income
-16.2-7.68-2.91-0.57
Interest & Investment Income
0.030.142.84-
Other Non Operating Income (Expenses)
4.530.24--
EBT Excluding Unusual Items
-11.64-7.3-0.07-0.57
Gain (Loss) on Sale of Investments
----0
Other Unusual Items
3.340.01--
Pretax Income
-8.3-7.29-0.07-0.57
Income Tax Expense
--0.6-0.03
Net Income
-8.3-7.29-0.67-0.54
Preferred Dividends & Other Adjustments
2.78--36.16
Net Income to Common
-11.09-7.29-0.67-36.71
Shares Outstanding (Basic)
1-00
Shares Outstanding (Diluted)
1-00
Shares Change (YoY)
--133.12%-
EPS (Basic)
-21.72--2.97-
EPS (Diluted)
-21.72--2.97-
EBITDA
-15.76-7.21--
D&A For EBITDA
0.440.46--
EBIT
-16.2-7.68-2.91-0.57
Updated Nov 20, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q